Moorestown, New Jersey, United States
seeking biotech alpha August 2019 & November 2018 insight
KEYTRUDA® (pembrolizumab)
Emgality® (galcanezumab-gnlm)
Emgality® (galcanezumab-gnlm)
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)
Wed November 14, 2018 6:45 AM|Business Wire|About: MRK
Emgality® (galcanezumab-gnlm)
Emgality® (galcanezumab-gnlm)
Emgality® (galcanezumab-gnlm)
Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
08/05/2019
Failure to respond to migraine preventive treatments is a common occurrence; internationally it is estimated that more than 40% of patients who use migraine preventive medications have a history of failure or switching treatments(1)
INDIANAPOLIS, Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)
AZEDRA® (iobenguane I 131)
Emgality® (galcanezumab-gnlm)
AZEDRA® (iobenguane I 131)
CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131)
Tue August 6, 2019 8:30 AM|GlobeNewswire|About: PGNXGlobeNewswire
NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (PGNX),
https://www.progenics.com/product-pipeline/overview/
V920 (rVSV∆G-ZEBOV-GP)
V920 (rVSV∆G-ZEBOV-GP)
AZEDRA® (iobenguane I 131)
Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration
Tue November 13, 2018 4:35 PM|Business Wire|About: MRK
Celgene (CELG)
V920 (rVSV∆G-ZEBOV-GP)
Celgene (CELG)
Lyfebulb Partners with Celgene to Inspire Patient-Driven Innovation in the Management of Multiple Sclerosis
Wed November 14, 2018 7:58 AM|PR Newswire|About: CELG
NEW YORK, Nov. 14, 2018 /PRNewswire/
Elagolix
V920 (rVSV∆G-ZEBOV-GP)
Celgene (CELG)
November 14, 2018
AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress
NORTH CHICAGO, Ill., Nov. 14, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV)
seeking biotech alpha August 2019 & November 2018 insight
Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab)
Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab)
Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab)
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Thu August 1, 2019 7:00 AM|PR Newswire|About: BMY, NKTR
SAN FRANCISCO, Aug. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY)
Triple Combination of VX-659, Tezacaftor and Ivacaftor
Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab)
Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab)
Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis
Tue November 27, 2018 8:00 AM|Business Wire|About: VRTX
CALQUENCE® (acalabrutinib) and LUMOXITI™ (moxetumomab pasudotox-tdfk)
Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab)
CALQUENCE® (acalabrutinib) and LUMOXITI™ (moxetumomab pasudotox-tdfk)
AstraZeneca Presents Clinical Research Advances for Blood Cancer Patients at 2018 American Society of Hematology Annual Meeting
Tue November 27, 2018 7:00 AM|Business Wire|About: AZN
CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia
Wed August 14, 2019 8:00 AM|Business Wire|About: AZN
Designation based on positive results from two Phase III trials
WILMINGTON, Del.--(BUSINESS WIRE)
LYRICA® (pregabalin)
generic version of EpiPen®1 (epinephrine injection, USP) Auto-Injector, 0.3 mg
CALQUENCE® (acalabrutinib) and LUMOXITI™ (moxetumomab pasudotox-tdfk)
Pfizer Receives Six Months Pediatric Exclusivity for LYRICA® (pregabalin)
Tue November 27, 2018 3:01 PM|Business Wire|About: PFE
Jivi (PEGylated recombinant Factor VIII)
generic version of EpiPen®1 (epinephrine injection, USP) Auto-Injector, 0.3 mg
generic version of EpiPen®1 (epinephrine injection, USP) Auto-Injector, 0.3 mg
Bayer's hemophilia A treatment Jivi OK'd in Europe
Nov. 27, 2018 11:15 AM ET|About: Bayer A.G. ADR (BAYRY)|By: Douglas W. House, SA News Editor
generic version of EpiPen®1 (epinephrine injection, USP) Auto-Injector, 0.3 mg
generic version of EpiPen®1 (epinephrine injection, USP) Auto-Injector, 0.3 mg
generic version of EpiPen®1 (epinephrine injection, USP) Auto-Injector, 0.3 mg
seeking biotech alpha August 2019 & November 2018 insight
Valiant Navion thoracic stent graft system
(GILD) antiviral Remdesivir and 3 monoclonal antibody: ZMapp, mAb 114 and (REGN) 3470-3471-3479
Swedish Orphan Biovitrum AB (OTCPK:BIOVF) (Sobi)
Medtronic's Valiant Navion stent CE Mark'd
Nov. 13, 2018 10:23 AM ET|About: Medtronic plc (MDT)|By: Douglas W. House, SA News Editor
Swedish Orphan Biovitrum AB (OTCPK:BIOVF) (Sobi)
(GILD) antiviral Remdesivir and 3 monoclonal antibody: ZMapp, mAb 114 and (REGN) 3470-3471-3479
Swedish Orphan Biovitrum AB (OTCPK:BIOVF) (Sobi)
Sobi to acquire U.S. rights to AstraZeneca's Synagis and half interest in MEDI8897 for $1.5B
Nov. 13, 2018 8:34 AM ET|About: AstraZeneca Group plc (AZN)|By: Douglas W. House, SA News Editor
(GILD) antiviral Remdesivir and 3 monoclonal antibody: ZMapp, mAb 114 and (REGN) 3470-3471-3479
(GILD) antiviral Remdesivir and 3 monoclonal antibody: ZMapp, mAb 114 and (REGN) 3470-3471-3479
(GILD) antiviral Remdesivir and 3 monoclonal antibody: ZMapp, mAb 114 and (REGN) 3470-3471-3479
Ebola clinical trial to begin in DRC
Nov. 13, 2018 4:49 AM ET|By: Yoel Minkoff, SA News Editor
Helen Branswell
MAVYRET™ (glecaprevir/pibrentasvir)
MAVYRET™ (glecaprevir/pibrentasvir)
(GILD) antiviral Remdesivir and 3 monoclonal antibody: ZMapp, mAb 114 and (REGN) 3470-3471-3479
Enanta’s HCV Collaboration Partner AbbVie receives Approval by the European Commission for MAVIRET™ (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve HCV Patients with Compensated Cirrhosis
Fri August 2, 2019 8:51 AM|Business Wire|About: ENTA
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (ENTA)
NovoCure (NVCR)
MAVYRET™ (glecaprevir/pibrentasvir)
Eliquis® (apixaban)
Eliquis® (apixaban)
MAVYRET™ (glecaprevir/pibrentasvir)
Eliquis® (apixaban)
Real-World Evidence on Patients Aged 80 and Older Presented From ARISTOPHANES, the Largest Real-World Data Study Evaluating Oral Anticoagulants Among Patients with Non-Valvular Atrial Fibrillation
Eliquis® (apixaban) was associated with lower rates of stroke or systemic embolism and major bleeding in elderly patient populations when compared to rivaroxaban and dabigatran
(PRINCETON, N.J. & NEW YORK) November 11, 2018 – The Bristol-Myers Squibb-Pfizer Alliance
seeking biotech alpha August 2019 & November 2018 insight
LENVIMA® (lenvatinib), in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab)
LENVIMA® (lenvatinib), in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab)
LENVIMA® (lenvatinib), in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab)
New Data from Investigational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
Fri November 9, 2018 6:45 AM|Business Wire|About: MRK
TOKYO & KENILWORTH, N.J.--(BUSINESS WIRE)-- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Merck (MRK), known as MSD outside the United States and Canada,
FARXIGA (dapagliflozin)
LENVIMA® (lenvatinib), in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab)
LENVIMA® (lenvatinib), in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab)
FARXIGA Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabetes in the Landmark DECLARE-TIMI 58 Trial
Sat November 10, 2018 4:45 PM|Business Wire|About: AZN
LYNPARZA® (olaparib)
LENVIMA® (lenvatinib), in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab)
Repatha® (Evolocumab)
Lynparza Phase III PROfound trial in HRR* mutation-selected metastatic castration-resistant prostate cancer met primary endpoint
PUBLISHED7 August 2019
7 August 2019 07:00 BST
AstraZeneca and MSD’s Lynparza met the primary endpoint of significantly increasing the time patients selected for BRCA1/2 or ATM mutations live without radiographic disease progression vs. standard of care treatment
Only PARP inhibitor with positive Phase III results in four different cancer types (ovarian, breast, pancreatic and prostate)
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc
AstraZeneca and Merck's Lynparza shows treatment benefit in late-stage prostate cancer study
Aug. 7, 2019 7:04 AM ET|About: AstraZeneca PLC (AZN)|By: Douglas W. House, SA News Editor
Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer
14 August 2019 07:00 BST
AstraZeneca and MSD’s Lynparza, when added to standard-of-care bevacizumab, significantly increased the time women lived without disease progression
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada)
Repatha® (Evolocumab)
Mirati Therapeutics' (MRTX) mocetinostat, (HDAC) inhibitor, with (AZN) Imfinzi (durvalumab)
Repatha® (Evolocumab)
Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018
Mon November 12, 2018 4:00 PM|PR Newswire|About: AMGN
THOUSAND OAKS, Calif., Nov. 12, 2018 /PRNewswire/ -- Amgen (AMGN)
Mirati Therapeutics' (MRTX) mocetinostat, (HDAC) inhibitor, with (AZN) Imfinzi (durvalumab)
Mirati Therapeutics' (MRTX) mocetinostat, (HDAC) inhibitor, with (AZN) Imfinzi (durvalumab)
Mirati Therapeutics' (MRTX) mocetinostat, (HDAC) inhibitor, with (AZN) Imfinzi (durvalumab)
Mirati's mocetinostat + AstraZeneca's Imfinzi show positive effect in mid-stage lung cancer study
Nov. 9, 2018 9:30 AM ET|About: AstraZeneca Group plc (AZN)|By: Douglas W. House, SA News Editor
Praluent® (alirocumab)
Mirati Therapeutics' (MRTX) mocetinostat, (HDAC) inhibitor, with (AZN) Imfinzi (durvalumab)
Mirati Therapeutics' (MRTX) mocetinostat, (HDAC) inhibitor, with (AZN) Imfinzi (durvalumab)
ODYSSEY OUTCOMES Investigators Highlight at AHA that Praluent® (alirocumab) Injection Was Associated with Fewer Deaths from Any Cause
Sun November 11, 2018 8:14 AM|PR Newswire|About: REGN
TARRYTOWN, N.Y. and PARIS, Nov. 11, 2018 /PRNewswire/ --
seeking biotech alpha Sept/Aug 2019 & Nov 2018 insight
Repatha® (Evolocumab)
Selpercatinib (LOXO-292)
Selpercatinib (LOXO-292)
Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018
Mon November 5, 2018 4:00 PM|PR Newswire|About: AMGN
Selpercatinib (LOXO-292)
Selpercatinib (LOXO-292)
Selpercatinib (LOXO-292)
Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
Mon September 9, 2019 3:20 AM|PR Newswire|About: LLY
PR Newswire
INDIANAPOLIS, Sept. 9, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY)
Dupixent® (dupilumab)
Selpercatinib (LOXO-292)
Icosapent Ethyl Recognized as Only Non-LDL-Cholesterol Lipid Management Treatment with Cardiovascula
Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis
Tue August 6, 2019 1:04 AM|PR Newswire|About: REGN
TARRYTOWN, N.Y. and PARIS, Aug. 6, 2019 /PRNewswire/ --
U.S. FDA submission for children planned for 4Q 2019
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi
Icosapent Ethyl Recognized as Only Non-LDL-Cholesterol Lipid Management Treatment with Cardiovascula
Icosapent Ethyl Recognized as Only Non-LDL-Cholesterol Lipid Management Treatment with Cardiovascula
Icosapent Ethyl Recognized as Only Non-LDL-Cholesterol Lipid Management Treatment with Cardiovascula
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognizes Importance of Addressing Residual Cardiovascular Risk in Patients on Statins
Mon September 16, 2019 6:00 AM|GlobeNewswire|About: AMRN
Millions of Patients on Statins with Elevated Triglycerides Are at Risk of Cardiovascular Events, Such as Heart Attack, Stroke or Death
Icosapent Ethyl Recognized as Only Non-LDL-Cholesterol Lipid Management Treatment with Cardiovascular Risk Reduction Outcomes Results
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN)
Eli Lilly and Company (LLY) and NextCure, Inc.
Icosapent Ethyl Recognized as Only Non-LDL-Cholesterol Lipid Management Treatment with Cardiovascula
Eli Lilly and Company (LLY) and NextCure, Inc.
Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines
Mon November 5, 2018 4:30 PM|PR Newswire|About: LLY
REGN-EB3 THERAPY
Icosapent Ethyl Recognized as Only Non-LDL-Cholesterol Lipid Management Treatment with Cardiovascula
Eli Lilly and Company (LLY) and NextCure, Inc.
August 12, 2019 at 10:01 AM EDT
PALM EBOLA CLINICAL TRIAL STOPPED EARLY AS REGENERON'S REGN-EB3 THERAPY SHOWS SUPERIORITY TO ZMAPP IN PREVENTING EBOLA DEATHS
TARRYTOWN, N.Y., Aug. 12, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
seeking biotech alpha August 2019 & November 2018 insight
Illumina, Inc. (ILMN) and Pacific Biosciences (PACB)
Illumina, Inc. (ILMN) and Pacific Biosciences (PACB)
Illumina, Inc. (ILMN) and Pacific Biosciences (PACB)
Amgen (AMGN)
Illumina, Inc. (ILMN) and Pacific Biosciences (PACB)
Illumina, Inc. (ILMN) and Pacific Biosciences (PACB)
Tecentriq® (ATEZOLIZUMAB)
Illumina, Inc. (ILMN) and Pacific Biosciences (PACB)
Bavarian Nordic A/S's (BVNKF) CV301, combined with (AZN) PD-L1 inhibitor IMFINZI (durvalumab)
Genentech’s Tecentriq® (ATEZOLIZUMAB) Plus Platinum-based Chemotherapy Reduced the Risk of Disease Worsening or Death in People With Previously Untreated Advanced Bladder Cancer
Mon August 5, 2019 1:00 AM|Business Wire|About: RHHBY
– IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer –
– Data will be shared with health authorities globally, including the U.S. Food and Drug Administration (FDA) –
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)
Bavarian Nordic A/S's (BVNKF) CV301, combined with (AZN) PD-L1 inhibitor IMFINZI (durvalumab)
Bavarian Nordic A/S's (BVNKF) CV301, combined with (AZN) PD-L1 inhibitor IMFINZI (durvalumab)
Bavarian Nordic A/S's (BVNKF) CV301, combined with (AZN) PD-L1 inhibitor IMFINZI (durvalumab)
Bavarian Nordic launches Phase 1/2 study of prime/boost vaccine CV301 in colorectal and pancreatic cancers
Nov. 2, 2018 11:47 AM ET|By: Douglas W. House, SA News Editor
Elagolix
Bavarian Nordic A/S's (BVNKF) CV301, combined with (AZN) PD-L1 inhibitor IMFINZI (durvalumab)
BioArctic and AbbVie - BAN0805
BioArctic and AbbVie - BAN0805
Bavarian Nordic A/S's (BVNKF) CV301, combined with (AZN) PD-L1 inhibitor IMFINZI (durvalumab)
BioArctic and AbbVie - BAN0805
seeking biotech alpha August 2019 November 2018 insight
PROMACTA (eltrombopag)
Tivicay (dolutegravir) + lamivudine
Tivicay (dolutegravir) + lamivudine
FDA OKs expanded use for Novartis' Promacta
Nov. 16, 2018 4:43 PM ET|About: Novartis AG (NVS)|By: Douglas W. House, SA News Editor
Tivicay (dolutegravir) + lamivudine
Tivicay (dolutegravir) + lamivudine
Tivicay (dolutegravir) + lamivudine
European advisory group backs ViiV Healthcare's Tivicay + lamivudine in HIV-1
Nov. 19, 2018 7:14 AM ET|By: Douglas W. House, SA News Editor
Descovy for PrEP™
Tivicay (dolutegravir) + lamivudine
TAGRISSO® (OSIMERTINIB)
August 08, 2019
Gilead Sciences Statement on U.S. Food and Drug Administration Advisory Committee’s Recommendation on Descovy for PrEP™
FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 7, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD
TAGRISSO® (OSIMERTINIB)
Bria-IMT™ in combination with pembrolizumab [KEYTRUDA®
TAGRISSO® (OSIMERTINIB)
TAGRISSO® (OSIMERTINIB) Significantly Improves Overall Survival in the Phase III FLAURA Trial for 1st-line EGFR-mutated Non-small Cell Lung Cancer
Fri August 9, 2019 7:00 AM|Business Wire|About: AZN
TAGRISSO is the only medicine demonstrating statistically-significant overall survival benefit in this setting. Also increased the time patients with central nervous system metastases lived without disease progression
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca
Bria-IMT™ in combination with pembrolizumab [KEYTRUDA®
Bria-IMT™ in combination with pembrolizumab [KEYTRUDA®
Bria-IMT™ in combination with pembrolizumab [KEYTRUDA®
Nucala (mepolizumab)
Bria-IMT™ in combination with pembrolizumab [KEYTRUDA®
Bria-IMT™ in combination with pembrolizumab [KEYTRUDA®
Glaxo files U.S. marketing application for expanded use of Nucala
Nov. 19, 2018 7:46 AM ET|By: Douglas W. House, SA News Editor
seeking biotech alpha August 2019 & November 2018 insight
DAURISMO™ (glasdegib)
VENCLEXTA® (venetoclax)
VENCLEXTA® (venetoclax)
U.S. FDA Approves DAURISMO™ (glasdegib) for Adult Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML) for Whom Intensive Chemotherapy is Not an Option
Wed November 21, 2018 1:40 PM|Business Wire|About: PFE
VENCLEXTA® (venetoclax)
VENCLEXTA® (venetoclax)
VENCLEXTA® (venetoclax)
AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
Wed November 21, 2018 2:14 PM|PR Newswire|About: ABBV
SIRTURO® (bedaquiline)
VENCLEXTA® (venetoclax)
SIRTURO® (bedaquiline)
Janssen Announces U.S. FDA Accelerated Approval for SIRTURO® (bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant Tuberculosis
Label expansion marks important milestone in Johnson & Johnson’s pediatric research and development program for bedaquiline
TITUSVILLE, NJ, August 9, 2019 — The Janssen Pharmaceutical Companies of Johnson & Johnson
BeiGene BGNE
Bria-IMT™ with KEYTRUDA®
SIRTURO® (bedaquiline)
Analysts Take Action on Health Care Stocks
JPMorgan initiates coverage of BeiGene, Brookline Capital Markets starts covering Celsion and Cellectar Biosciences
November 21, 2018
Bria-IMT™ with KEYTRUDA®
Bria-IMT™ with KEYTRUDA®
Bria-IMT™ with KEYTRUDA®
UPDATE - BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium
November 20, 2018 | About: BCTXF +0% MRK +0%
Note: This Press Release contains amendments to the press release previously issued on Nov. 19, 2018
BRACAnalysis CDx
Bria-IMT™ with KEYTRUDA®
Bria-IMT™ with KEYTRUDA®
Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer
Wed August 7, 2019 7:05 AM|GlobeNewswire|About: AZN, MYGN
SALT LAKE CITY, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics (MYGN), Inc. (NASDAQ: MYGN)
seeking biotech alpha August 2019 & November 2018 insight
EYLEA® (aflibercept) Injection Prefilled Syringe
EYLEA® (aflibercept) Injection Prefilled Syringe
EYLEA® (aflibercept) Injection Prefilled Syringe
FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe
Tue August 13, 2019 7:00 AM|PR Newswire|About: REGNQ2: 08-06-19 Earnings Summary
EPS of $6.02 beats by $0.60 Revenue of $1.93B (20.25% Y/Y) beats by $131.71M
TARRYTOWN, N.Y., Aug. 13, 2019 /PRNewswire/ -
Zanubrutinib and Tislelizumab
EYLEA® (aflibercept) Injection Prefilled Syringe
EYLEA® (aflibercept) Injection Prefilled Syringe
Priority Review Granted to BeiGene’s New Drug Applications for Zanubrutinib and Tislelizumab in China
Thu November 15, 2018 7:00 AM|GlobeNewswire|About: BGNE
CABOMETYX® (cabozantinib)
EYLEA® (aflibercept) Injection Prefilled Syringe
ADCETRIS® (Brentuximab Vedotin)
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) Tablets for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib
Thu November 15, 2018 1:32 AM|Business Wire|About: EXEL
ADCETRIS® (Brentuximab Vedotin)
ADCETRIS® (Brentuximab Vedotin)
ADCETRIS® (Brentuximab Vedotin)
FDA Grants Breakthrough Therapy Designation to ADCETRIS® (Brentuximab Vedotin) for Frontline Peripheral T-Cell Lymphomas
Thu November 15, 2018 8:00 AM|Business Wire|About: SGEN
DRG Invisible Trial System
ADCETRIS® (Brentuximab Vedotin)
DRG Invisible Trial System
New Approvals Allow Chronic Pain Sufferers to Try Abbott's Non-Opioid Pain Therapy Before Getting Device Implant
Thu November 15, 2018 9:00 AM|PR Newswire|About: ABT
CVS
ADCETRIS® (Brentuximab Vedotin)
DRG Invisible Trial System
CVS Health Teams Up with Philadelphia Job Corps, Philadelphia Works and Philadelphia Youth Network to Open New Mock Pharmacy for Aspiring Pharmacy Technicians
Thu November 15, 2018 8:00 AM|PR Newswire|About: CVS
PHILADELPHIA, Nov. 15, 2018 /PRNewswire/
seeking biotech alpha August 2019 & November 2018 insight
oral semaglutide
LUXTURNA® (voretigene neparvovec)
LUXTURNA® (voretigene neparvovec)
Novo Nordisk's PIONEER 9 trial successfully meets primary endpoints
Nov. 23, 2018 7:40 AM ET|About: Novo Nordisk A/S (NVO)|By: Mamta Mayani, SA News Editor
LUXTURNA® (voretigene neparvovec)
LUXTURNA® (voretigene neparvovec)
LUXTURNA® (voretigene neparvovec)
European Commission Approves Spark Therapeutics’ LUXTURNA® (voretigene neparvovec), a One-time Gene Therapy for Inherited Retinal Disease Caused by Confirmed Biallelic RPE65 Mutations
Fri November 23, 2018 1:15 AM|GlobeNewswire
Spark Therapeutics (ONCE) will manufacture and supply LUXTURNA for Novartis, while Novartis has exclusive rights to pursue development, registration and commercialization in all other countries outside the U.S.
PHILADELPHIA, Nov. 23, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics
Imbruvica®▼(ibrutinib)
LUXTURNA® (voretigene neparvovec)
Imbruvica®▼(ibrutinib)
Janssen Announces European Commission Approval of Imbruvica®▼(ibrutinib) for Expanded Use in Two Indications
Decision represents the fifth European approval in five years
August 13, 2019 07:08 AM Eastern Daylight Time
BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson
Fasenra
Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd)
Imbruvica®▼(ibrutinib)
AstraZeneca's Fasenra an Orphan Drug in U.S. for rare type of blood vessel inflammation
Nov. 26, 2018 6:46 AM ET|About: AstraZeneca Group plc (AZN)|By: Douglas W. House, SA News Editor
Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd)
Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd)
Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd)
European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Tue August 27, 2019 4:16 PM|Business Wire|About: BMY
JULUCA
Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd)
Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd)
ViiV Healthcare's HIV med Juluca OK'd in Japan
Nov. 26, 2018 7:33 AM ET|By: Douglas W. House, SA News Editor
seeking biotech alpha November 2018 insight
Verzenio® (abemaciclib)
DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) + once-daily PIFELTRO (doravirine)
DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) + once-daily PIFELTRO (doravirine)
Lilly to Present Clinical Data for Verzenio® (abemaciclib) and Real-World Evidence across HR+, HER2- Metastatic Breast Cancer at 2018 SABCS
Thu November 29, 2018 6:45 AM|PR Newswire|About: LLY
DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) + once-daily PIFELTRO (doravirine)
DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) + once-daily PIFELTRO (doravirine)
DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) + once-daily PIFELTRO (doravirine)
European Commission Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients
Wednesday, November 28, 2018 4:30 pm EST KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK)
Xalatan
DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) + once-daily PIFELTRO (doravirine)
Amgen Inc. (AMGN)
Eyenovia's micro-dose latanoprost shows positive effect in mid-stage study
Nov. 28, 2018 4:33 PM ET|By: Douglas W. House, SA News Editor
Amgen Inc. (AMGN)
ALKS 3831 (olanzapine/samidorphan)
Amgen Inc. (AMGN)
Amgen opts in on second cancer program with Nuevolution
Nov. 29, 2018 6:55 AM ET|About: Amgen Inc. (AMGN)|By: Douglas W. House, SA News Editor
ALKS 3831 (olanzapine/samidorphan)
ALKS 3831 (olanzapine/samidorphan)
ALKS 3831 (olanzapine/samidorphan)
Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia
Thu November 29, 2018 7:01 AM|PR Newswire|About: ALKS
Varian (VAR)
ALKS 3831 (olanzapine/samidorphan)
ALKS 3831 (olanzapine/samidorphan)
Varian Halcyon Treatment System Receives China NMPA Approval
Wed November 28, 2018 4:10 PM|PR Newswire|About: VAR
seeking biotech alpha November 2018 insight
ACTPen™ 162 mg/0.9 mL, a single-dose prefilled autoinjector for Actemra® (tocilizumab)
ACTPen™ 162 mg/0.9 mL, a single-dose prefilled autoinjector for Actemra® (tocilizumab)
ACTPen™ 162 mg/0.9 mL, a single-dose prefilled autoinjector for Actemra® (tocilizumab)
EPIDIOLEX (cannabidiol)
ACTPen™ 162 mg/0.9 mL, a single-dose prefilled autoinjector for Actemra® (tocilizumab)
ACTPen™ 162 mg/0.9 mL, a single-dose prefilled autoinjector for Actemra® (tocilizumab)
GW Pharma's Epidiolex successful in second late-stage study in Dravet syndrome
Nov. 26, 2018 7:16 AM ET|About: GW Pharmaceuticals plc (GWPH)|By: Douglas W. House, SA News Editor
NeuVax (nelipepimut-S), combined with Roche's (RHHBY) Herceptin (trastuzumab)
ACTPen™ 162 mg/0.9 mL, a single-dose prefilled autoinjector for Actemra® (tocilizumab)
NeuVax (nelipepimut-S), combined with Roche's (RHHBY) Herceptin (trastuzumab)
Opthea completes enrollment in mid-stage study of OPT-302 in wet AMD
Nov. 26, 2018 11:48 AM ET|About: Opthea Limited ADR (CKDXY)|By: Douglas W. House, SA News Editor
Zymeworks’ Azymetric™ and EFECT™
Zymeworks’ Azymetric™ and EFECT™
NeuVax (nelipepimut-S), combined with Roche's (RHHBY) Herceptin (trastuzumab)
Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ Platforms Globally
Tue November 27, 2018 6:30 AM|Business Wire|About: BGNE, ZYME
Vitrakvi® (larotrectinib)
Zymeworks’ Azymetric™ and EFECT™
Vitrakvi® (larotrectinib)
FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)
Mon November 26, 2018 7:16 PM|GlobeNewswire|About: LOXO
bb2121
Zymeworks’ Azymetric™ and EFECT™
Vitrakvi® (larotrectinib)
Celgene Corporation and bluebird bio Complete Enrollment of Pivotal KarMMa Study of anti-BCMA Car T Cell Therapy bb2121 in Patients with Relapsed and Refractory Multiple Myeloma
Tue November 27, 2018 7:30 AM|Business Wire|About: BLUE, CELG
SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (CELG) and bluebird bio, Inc. (BLUE)
seeking biotech alpha August 2019 & November 2018 insight
HUMIRA® (adalimumab)
Empliciti (elotuzumab), in combination with Celgene's Pomalyst (pomalidomide) and dexamethason
Empliciti (elotuzumab), in combination with Celgene's Pomalyst (pomalidomide) and dexamethason
November 6, 2018
AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Momenta
NORTH CHICAGO, Ill., Nov. 6, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV)
Empliciti (elotuzumab), in combination with Celgene's Pomalyst (pomalidomide) and dexamethason
Empliciti (elotuzumab), in combination with Celgene's Pomalyst (pomalidomide) and dexamethason
Empliciti (elotuzumab), in combination with Celgene's Pomalyst (pomalidomide) and dexamethason
FDA OKs Bristol-Myers Squibb's Empliciti for treatment-resistant myeloma
Nov. 6, 2018 4:51 PM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor
Johnson & Johnson Vision
Empliciti (elotuzumab), in combination with Celgene's Pomalyst (pomalidomide) and dexamethason
Johnson & Johnson Vision
Two Studies Measure Performance of ACUVUE OASYS with Transitions Light Intelligent Technology Contact Lenses in Simulated Sunlight, Day and Night Driving Conditions
Tue November 6, 2018 9:19 AM|PR Newswire|About: JNJ
ALKS 4230
anti-CEA CAR-T utilizing a Pressure-Enabled Drug Delivery (PEDD) by TriSalus™ Life Sciences.
Johnson & Johnson Vision
Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting
Tue November 6, 2018 8:01 AM|PR Newswire|About: ALKS
anti-CEA CAR-T utilizing a Pressure-Enabled Drug Delivery (PEDD) by TriSalus™ Life Sciences.
anti-CEA CAR-T utilizing a Pressure-Enabled Drug Delivery (PEDD) by TriSalus™ Life Sciences.
anti-CEA CAR-T utilizing a Pressure-Enabled Drug Delivery (PEDD) by TriSalus™ Life Sciences.
Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases
Tue November 6, 2018 8:01 AM|GlobeNewswire|About: SRNE
SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE) ("Sorrento")
Insulet Corporation’s Omnipod® DASH™ Insulin Management System
anti-CEA CAR-T utilizing a Pressure-Enabled Drug Delivery (PEDD) by TriSalus™ Life Sciences.
anti-CEA CAR-T utilizing a Pressure-Enabled Drug Delivery (PEDD) by TriSalus™ Life Sciences.
TUV Rheinland OpenSky helps insulin pump by Insulet achieve cybersecurity certification by DTSec
Tue November 6, 2018 11:59 AM|GlobeNewswire|About: PODD
COLOGNE, Germany and LITTLETON, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE)
Insulet (PODD) Presents At Canaccord Genuity Growth Conference - Slideshow
Aug. 13, 2019 2:31 PM ET | About: Insulet Corporation (PODD)
seeking biotech alpha August 2019 & November 2018 insight
Rozlytrek™ (entrectinib)
ibrutinib (Imbruvica®) & venetoclax (Venclexta®
Rozlytrek™ (entrectinib)
FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors
Thu August 15, 2019 4:10 PM|Business Wire|About: RHHBY
– First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain –
– Genentech’s first FDA-approved tumor-agnostic medicine –
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)
Medtronic plc (MDT)
ibrutinib (Imbruvica®) & venetoclax (Venclexta®
Rozlytrek™ (entrectinib)
Medtronic Q2 revenues up 6%; non-GAAP EPS up 14%; raises revenue growth guidance
Nov. 20, 2018 7:10 AM ET|About: Medtronic plc (MDT)|By: Mamta Mayani, SA News Editor
ibrutinib (Imbruvica®) & venetoclax (Venclexta®
ibrutinib (Imbruvica®) & venetoclax (Venclexta®
ibrutinib (Imbruvica®) & venetoclax (Venclexta®
AbbVie to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at 2018 American Society of Hematology Annual Meeting & Exposition
Tue November 20, 2018 8:32 AM|PR Newswire|About: ABBV
AVYCAZ (ceftazidime and avibactam)
AVYCAZ (ceftazidime and avibactam)
ibrutinib (Imbruvica®) & venetoclax (Venclexta®
FDA accepts Allergan's sNDA for AVYCAZ
Nov. 20, 2018 7:54 AM ET|About: Allergan plc (AGN)|By: Mamta Mayani, SA News Editor
reSET®
AVYCAZ (ceftazidime and avibactam)
MDT, MZOR, MZRTF
Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder
Mon November 19, 2018 6:46 PM|GlobeNewswire|About: NVS
seeking biotech alpha August 2019 & November 2018 insight
Entresto (sacubitril/valsartan)
Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI) and (JNJ) Vision
Entresto (sacubitril/valsartan)
Novartis' Entresto beats enalapril in heart failure study
Nov. 12, 2018 7:46 AM ET|About: Novartis AG (NVS)|By: Douglas W. House, SA News Editor
Impella CP®
Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI) and (JNJ) Vision
Entresto (sacubitril/valsartan)
FDA Safety Study of Unloading the Left Ventricle for 30 Minutes Prior to Reperfusion in Heart Attack Patients is Safe and Feasible
Abiomed will initiate pivotal randomized controlled trial with FDA
CHICAGO--(BUSINESS WIRE)--Nov. 11, 2018-- Abiomed (NASDAQ: ABMD)
Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI) and (JNJ) Vision
Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI) and (JNJ) Vision
Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI) and (JNJ) Vision
Singapore National Eye Centre, Singapore Eye Research Institute And Johnson & Johnson Vision Set Sights On Halting Global Myopia Epidemic
Mon November 12, 2018 1:30 AM|PR Newswire|About: JNJ
SINGAPORE, Nov. 12, 2018 /PRNewswire/
Approval Marks 14th Indication for KEYTRUDA
filgotinib, an investigational, oral, selective JAK1 inhibitor
Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI) and (JNJ) Vision
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib
Fri November 9, 2018 4:21 PM|Business Wire|About: MRK
Illumina (ILMN)
filgotinib, an investigational, oral, selective JAK1 inhibitor
filgotinib, an investigational, oral, selective JAK1 inhibitor
Illumina’s Growth Shows No Signs of Slowing Down
Illumina's recent acquisition of Pacific Biosciences of California strongly strengthens its product offering and ensures growth for years to come
filgotinib, an investigational, oral, selective JAK1 inhibitor
filgotinib, an investigational, oral, selective JAK1 inhibitor
filgotinib, an investigational, oral, selective JAK1 inhibitor
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
Thu August 15, 2019 4:01 PM|Business Wire|About: GILD, GLPG
FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) and Galapagos NV (GLPGF) (Euronext & NASDAQ: GLPG)
seeking biotech alpha August 2019 & November 2018 insight
DSUVIA™
Kymriah® (tisagenlecleucel)
LORBRENA® (lorlatinib)
AcelRx announces FDA approval of DSUVIA™
REDWOOD CITY, Calif., Nov. 2, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX),
LORBRENA® (lorlatinib)
Kymriah® (tisagenlecleucel)
LORBRENA® (lorlatinib)
U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC
Fri November 2, 2018 4:42 PM|Business Wire|About: PFE
Kymriah® (tisagenlecleucel)
Kymriah® (tisagenlecleucel)
evinacumab, an investigational angiopoietin-like 3 (ANGPTL3) antibody
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
Fri November 2, 2018 5:27 PM|PR Newswire|About: NVS
EAST HANOVER, N.J., Nov. 2, 2018 /PRNewswire/
evinacumab, an investigational angiopoietin-like 3 (ANGPTL3) antibody
evinacumab, an investigational angiopoietin-like 3 (ANGPTL3) antibody
evinacumab, an investigational angiopoietin-like 3 (ANGPTL3) antibody
August 14, 2019 at 7:00 AM EDT Back
REGENERON ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 TRIAL OF EVINACUMAB IN PATIENTS WITH SEVERE, INHERITED FORM OF HIGH CHOLESTEROL
TARRYTOWN, N.Y., Aug. 14, 2019 /PRNewswire/ --
Adding evinacumab reduced LDL cholesterol by 49% in patients with homozygous familial hypercholesterolemia, compared to lipid-lowering therapies alone
Evinacumab was generally well-tolerated, and all evinacumab patients completed the six-month treatment period
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN
SOLIRIS® (eculizumab)
evinacumab, an investigational angiopoietin-like 3 (ANGPTL3) antibody
SOLIRIS® (eculizumab)
European Commission Approves SOLIRIS® (eculizumab) For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Tue August 27, 2019 8:30 AM|Business Wire|About: ALXN
- SOLIRIS® (eculizumab) is the first and only approved medication for NMOSD in Europe -
- 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63% receiving placebo at 48 weeks -
BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (ALXN)
Pamiparib (BGB-290)
evinacumab, an investigational angiopoietin-like 3 (ANGPTL3) antibody
SOLIRIS® (eculizumab)
BeiGene to Present Clinical Data on PARP Inhibitor Pamiparib at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Mon November 5, 2018 7:00 AM|GlobeNewswire|About: BGNE
seeking biotech alpha November 2018 insight
BLINCYTO® (Blinatumomab)
Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab)
ADCETRIS® (Brentuximab Vedotin)
Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Fri November 16, 2018 9:00 AM|PR Newswire|About: AMGN
ADCETRIS® (Brentuximab Vedotin)
Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab)
ADCETRIS® (Brentuximab Vedotin)
Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
Fri November 16, 2018 10:52 AM|Business Wire|About: SGEN
Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab)
Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab)
Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab)
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
Thu November 15, 2018 4:30 PM|Business Wire|About: BMY
ACUVUE OASYS
PARP inhibitor pamiparib, combined with radiation therapy and/or the chemo agent temozolomide
Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab)
ACUVUE OASYS with Transitions Light Intelligent Technology Named Among TIME's 'Best Inventions of 2018'
Fri November 16, 2018 7:03 AM|PR Newswire|About: JNJ
JACKSONVILLE, Fla., Nov. 16, 2018 /PRNewswire/
Agilent Technologies Inc (A)
PARP inhibitor pamiparib, combined with radiation therapy and/or the chemo agent temozolomide
PARP inhibitor pamiparib, combined with radiation therapy and/or the chemo agent temozolomide
Agilent Expands Cell Analysis R&D Capabilities in Ireland
Fri November 16, 2018 11:00 AM|Business Wire|About: A
PARP inhibitor pamiparib, combined with radiation therapy and/or the chemo agent temozolomide
PARP inhibitor pamiparib, combined with radiation therapy and/or the chemo agent temozolomide
PARP inhibitor pamiparib, combined with radiation therapy and/or the chemo agent temozolomide
BeiGene's pamiparib shows positive action in Phase 1/2 brain cancer study
Nov. 16, 2018 7:56 AM ET|About: BeiGene (BGNE)|By: Douglas W. House, SA News Editor
seeking biotech alpha November 2018 insight
Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel])
Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel])
Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel])
FDA Grants Priority Review to Genentech’s Tecentriq in Combination with Abraxane for the Initial Treatment of People with PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
Tue November 13, 2018 1:06 AM|Business Wire|About: RHHBY
JPOD @ PHILADELPHIA
Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel])
Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel])
JPOD @ Philadelphia officially launched at Pennovation Works
JPOD @ Philadelphia, the first of its kind in the nation, is a networking hub that includes a secure telecommunications conferencing system to connect regional innovators to the J&J Innovation and JLABS network. It's about leveraging the talent-particularly in the health sciences-that is rampant and unique to Philadelphia, as well as boosting it.
READ MORE ›
November 13, 2018
GS-9674
Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel])
Bausch Health Companies Inc. (BHC)
Gilead's GS-9674 shows positive action in mid-stage NASH study
Nov. 9, 2018 8:35 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor
Bausch Health Companies Inc. (BHC)
Bausch Health Companies Inc. (BHC)
Bausch Health Companies Inc. (BHC)
AKCEA-APO(a)-Lrx
Bausch Health Companies Inc. (BHC)
Intuitive Surgical, Inc. (ISRG)
Akcea up 3% on positive AKCEA-APO(a)-Lrx data
Nov. 12, 2018 2:08 PM ET|About: Akcea Therapeutics (AKCA)|By: Douglas W. House, SA News Editor
collaboration partner Novartis (NVS)
Intuitive Surgical, Inc. (ISRG)
Bausch Health Companies Inc. (BHC)
Intuitive Surgical, Inc. (ISRG)
Intuitive Surgical Is Ironman For Doctors
Nov. 12, 2018 9:02 AM ET|8 comments | About: Intuitive Surgical, Inc. (ISRG)
seeking biotech alpha November 2018 insight
Opdivo (Nivolumab)
Amgen (AMGN) and Provention Bio, Inc. (PRVB)
Trulicity® (dulaglutide)
Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
Trulicity® (dulaglutide)
Amgen (AMGN) and Provention Bio, Inc. (PRVB)
Trulicity® (dulaglutide)
Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes
Mon November 5, 2018 6:45 AM|PR Newswire|About: LLYPR Newswire
INDIANAPOLIS, Nov. 5, 2018 /PRNewswire/
Amgen (AMGN) and Provention Bio, Inc. (PRVB)
Amgen (AMGN) and Provention Bio, Inc. (PRVB)
Amgen (AMGN) and Provention Bio, Inc. (PRVB)
Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease
Ocaliva® (obeticholic acid)
ADCETRIS® (Brentuximab Vedotin)
Amgen (AMGN) and Provention Bio, Inc. (PRVB)
Intercept Announces New OCA Data to be Presented at The Liver Meeting® 2018
Mon November 5, 2018 7:00 AM|GlobeNewswire|About: ICPT
JARDIANCE (empagliflozin)
ADCETRIS® (Brentuximab Vedotin)
ADCETRIS® (Brentuximab Vedotin)
Lilly's Jardiance reduced heart failure hospitalization risk in real-world study
Nov. 5, 2018 7:55 AM ET|By: Douglas W. House, SA News Editor
ADCETRIS® (Brentuximab Vedotin)
ADCETRIS® (Brentuximab Vedotin)
ADCETRIS® (Brentuximab Vedotin)
Seattle Genetics Submits Supplemental Biologics License Application for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
Mon November 5, 2018 8:00 AM|Business Wire|About: SGEN
seeking biotech alpha November 2018 insight
Abiomed, Inc. (ABMD)
SYMKEVI (tezacaftor/ivacaftor), combined with KALYDECO (ivacaftor)
VENCLYXTO® (venetoclax) Plus Rituximab
Abiomed Announces Q2 FY 2019 Record Revenue of $182 Million, up 37% Over Prior Year
Thu November 1, 2018 7:00 AM|GlobeNewswire|About: ABMD
DANVERS, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (ABMD)
VENCLYXTO® (venetoclax) Plus Rituximab
SYMKEVI (tezacaftor/ivacaftor), combined with KALYDECO (ivacaftor)
VENCLYXTO® (venetoclax) Plus Rituximab
AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Thu November 1, 2018 12:02 AM|PR Newswire|About: ABBV
SYMKEVI (tezacaftor/ivacaftor), combined with KALYDECO (ivacaftor)
SYMKEVI (tezacaftor/ivacaftor), combined with KALYDECO (ivacaftor)
SYMKEVI (tezacaftor/ivacaftor), combined with KALYDECO (ivacaftor)
Vertex Pharma's Symkevi OK'd in Europe
Nov. 1, 2018 7:05 AM ET|About: Vertex Pharmaceuticals... (VRTX)|By: Douglas W. House, SA News Editor
FARXIGA
umbralisib + ublituximab + Keytruda (pembrolizumab)
SYMKEVI (tezacaftor/ivacaftor), combined with KALYDECO (ivacaftor)
The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial of FARXIGA in Patients with Type 2 Diabetes to Be Featured at AHA 2018
Thu November 1, 2018 7:00 AM|Business Wire|About: AZN
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca
Novo Nordisk A/S (NVO)
umbralisib + ublituximab + Keytruda (pembrolizumab)
umbralisib + ublituximab + Keytruda (pembrolizumab)
Novo Nordisk Q3 revenues up 4%;
Nov. 1, 2018 6:24 AM ET|About: Novo Nordisk A/S (NVO)|By: Mamta Mayani, SA News Editor
umbralisib + ublituximab + Keytruda (pembrolizumab)
umbralisib + ublituximab + Keytruda (pembrolizumab)
umbralisib + ublituximab + Keytruda (pembrolizumab)
TG Therapeutics up 7% on positive umbralisib + ublituximab data
Nov. 1, 2018 11:04 AM ET|By: Douglas W. House, SA News Editor
The overall response rate (ORR) was 89% (n=8/9) in BTK-refractory chronic lymphocytic leukemia (CLL) patients receiving the combination of umbralisib + ublituximab + Merck's (MRK +0.1%) Keytruda (pembrolizumab).